Brenda Cooperstone

Brenda Cooperstone is recorded as Board Member at Lexeo Therapeutics, Inc. (LXEO) since January 1, 2023. The newest filing on record that lists Brenda Cooperstone as Board Member at Lexeo Therapeutics, Inc. (LXEO) is dated April 30, 2026. Earlier roles on record: Board Member at Senti Biosciences Holdings, Inc. (SNTI) until September 23, 2026. Senti Biosciences Holdings, Inc. reported in an 8-K filed September 24, 2026 that Brenda Cooperstone resigned as member and Chair of the Compensation Committee of the Board, effective September 23, 2026. Senti Biosciences Holdings, Inc. reported in an 8-K filed September 24, 2026 that Brenda Cooperstone resigned as member of the Board, effective September 23, 2026. Senti Biosciences Holdings, Inc. reported in an 8-K filed March 10, 2025 that Brenda Cooperstone resigned as member of the Audit Committee, effective March 7, 2025. Equibles holds 4 filed executive changes naming Brenda Cooperstone; each is listed under recent activity with its source filing. Lexeo Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lexeo Therapeutics, Inc. includes R. Nolan Townsend (CEO and Board Member), Kyle Rasbach (CFO and Chief Accounting Officer), Louis Tamayo (CFO) and 7 others.